Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer

Abstract

Irreversible electroporation (IRE) has been approved as ablation therapy for pancreatic ductal adenocarcinoma (PDAC). Here, the authors show that, in mouse models, IRE reverses the immunosuppressive microenvironment of PDAC resulting in increased and durable response when combined with PD1 checkpoint inhibition therapy.